Hanny Al-Samkari's guest appearances

Hanny Al-Samkari

BloodStream

Blood & Cancer

Oncology Today with Dr Neil Love

OwlTail

Dr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia. CME information and select publications here

Dr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia. CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayITP23" rel="nofollow" target="_blank">here</a>

Immune Thrombocytopenia Edition with Dr Hanny Al-Samkari

Kevin Kuo

Patrick is joined by dynamic duo, Dr. Kevin Kuo and Dr. Hanny Al-Samkari who share more about Alpha and Beta Thalassemia, a sister blood disorder to hemophilia. Plus, we’ll get an update on Patrick’s chronic pain &amp; Amy’s writing as well as a brand new Let’s Talk segment on aging and changing.    Show Notes: Let’s Talk is brought to you by Sanofi Metal Heath Educational Resources  Visit Shareyourwhy.com to meet the Sanofi CoRe team and hear from them and members of the community about their story and passion for the hemophilia community.   Portraits of Progress    Subscribe to BloodStream Podcast   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter

Patrick is joined by dynamic duo, Dr. Kevin Kuo and Dr. Hanny Al-Samkari who share more about Alpha and Beta Thalassemia, a sister blood disorder to hemophilia. Plus, we’ll get an update on Patrick’s chronic pain &amp; Amy’s writing as well as a brand new Let’s Talk segment on aging and changing.  Show Notes: Let’s Talk is brought to you by Sanofi <a href="https://letstalkmh.com/" rel="nofollow" target="_blank">Metal Heath Educational Resources </a> Visit <a href="http://Shareyourwhy.com" rel="nofollow" target="_blank">Shareyourwhy.com</a> to meet the Sanofi CoRe team and hear from them and members of the community about their story and passion for the hemophilia community. <a href="https://www.portraitsofprogress.com/" rel="nofollow" target="_blank">Portraits of Progress</a> <a href="https://podcasts.apple.com/us/podcast/bloodstream/id1133574474" rel="nofollow" target="_blank"> Subscribe to BloodStream Podcast</a> Connect with BloodStream Media: <a href="https://www.bloodstreammedia.com/" rel="nofollow" target="_blank">BloodStreamMedia.com</a> <a href="http://www.facebook.com/BloodStreamMedia" rel="nofollow" target="_blank">BloodStream on Facebook</a> <a href="https://twitter.com/BloodStreamInfo" rel="nofollow" target="_blank">BloodStream on Twitter</a>

Thalassemia’s dynamic duo, Dr. Kevin Kuo and Dr. Hanny Al-Samkari, plus aging and changing on Let’s Talk

Hanny Al-Samkari, MD, joins the podcast to discuss thrombosis in COVID-19 and lung cancer patients as well as the use of bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).  Dr. Al-Samkari, of Massachusetts General Hospital, presented three studies on these topics at the virtual ISTH 2020 Congress. In this episode, Dr. Al-Samkari describes these studies to host David H. Henry, MD.  Thrombosis, Bleeding, and the Effect of Anticoagulation on Survival in Critically Ill Patients with COVID-19 in the United States   This 67-center study included 3,239 critically ill adults with COVID-19. The 14-day incidence of radiographically confirmed venous thromboembolism (VTE) was 6.3%. The 14-day incidence of strictly defined major bleeding was 2.8%. Patients who received therapeutic anticoagulation in the first 2 days of ICU admission had a similar risk of death at 28 days as patients who did not receive anticoagulation.  Al-Samkari H et al. ISTH 2020, Abstract LB/CO01.2. https://bit.ly/3alvquE.  An International Multicenter Study of Bevacizumab for Bleeding in Hereditary Hemorrhagic Telangiectasia — The InHIBIT-Bleed Study   This 12-center trial included 238 patients with HHT. Patients received bevacizumab for a median of 12 months (range, 1-96 months). The most common dosing schedule was 5 mg/kg every 2-4 weeks for four to six treatments of induction, followed by maintenance. During the first year, bevacizumab increased the mean hemoglobin by 3.2 g/dL. At 6 months post treatment, transfusions of red blood cells had decreased by 82% and iron infusions had decreased by 70%.  Al-Samkari H et al. ISTH 2020, Abstract OC 9.2. https://bit.ly/30L5PrV.  The ALK Rearrangement is a Major Risk Factor for Venous and Arterial Thrombosis in Non–Small Cell Lung Cancer   This retrospective study included patients with advanced non–small cell lung cancer (NSCLC). There were 422 patients with ALK-rearranged NSCLC and 385 with non–ALK-rearranged NSCLC. The rate of initial VTE was 42.7% in ALK and 28.6% in non-ALK NSCLC. The rate of recurrent VTE was 13.5% in ALK and 3.1% in non-ALK NSCLC. Arterial thrombosis rates were similar in ALK and non-ALK NSCLC (5.0% and 4.4%, respectively). In analyses controlling for time and thrombosis risk factors, the risk of VTE was three times higher and the risk of arterial thrombosis was four times higher among patients with ALK rearrangement.  Al-Samkari H et al. ISTH 2020, Abstract OC 10.2. https://bit.ly/30KHouB. Disclosures: Dr. Al-Samkari has no relevant disclosures. Dr. Henry has no relevant disclosures. * * * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd

Hanny Al-Samkari, MD, joins the podcast to discuss thrombosis in COVID-19 and lung cancer patients as well as the use of bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). <a href="https://www.dfhcc.harvard.edu/insider/member-detail/member/hanny-al-samkari-md/" rel="nofollow" target="_blank"> Dr. Al-Samkari</a>, of Massachusetts General Hospital, presented three studies on these topics at the virtual ISTH 2020 Congress. In this episode, Dr. Al-Samkari describes these studies to host <a href="https://www.pennmedicine.org/providers/profile/david-henry" rel="noopener nofollow" target="_blank">David H. Henry, MD</a>. <ol> <li>Thrombosis, Bleeding, and the Effect of Anticoagulation on Survival in Critically Ill Patients with COVID-19 in the United States</li> </ol> <ul> <li>This 67-center study included 3,239 critically ill adults with COVID-19.</li> <li>The 14-day incidence of radiographically confirmed venous thromboembolism (VTE) was 6.3%.</li> <li>The 14-day incidence of strictly defined major bleeding was 2.8%.</li> <li>Patients who received therapeutic anticoagulation in the first 2 days of ICU admission had a similar risk of death at 28 days as patients who did not receive anticoagulation.</li> </ul> Al-Samkari H et al. ISTH 2020, Abstract LB/CO01.2. <a href="https://bit.ly/3alvquE" rel="nofollow" target="_blank">https://bit.ly/3alvquE</a>. <ol> <li>An International Multicenter Study of Bevacizumab for Bleeding in Hereditary Hemorrhagic Telangiectasia — The InHIBIT-Bleed Study</li> </ol> <ul> <li>This 12-center trial included 238 patients with HHT.</li> <li>Patients received bevacizumab for a median of 12 months (range, 1-96 months).</li> <li>The most common dosing schedule was 5 mg/kg every 2-4 weeks for four to six treatments of induction, followed by maintenance.</li> <li>During the first year, bevacizumab increased the mean hemoglobin by 3.2 g/dL.</li> <li>At 6 months post treatment, transfusions of red blood cells had decreased by 82% and iron infusions had decreased by 70%.</li> </ul> Al-Samkari H et al. ISTH 2020, Abstract OC 9.2. <a href="https://bit.ly/30L5PrV" rel="nofollow" target="_blank">https://bit.ly/30L5PrV</a>. <ol> <li>The ALK Rearrangement is a Major Risk Factor for Venous and Arterial Thrombosis in Non–Small Cell Lung Cancer</li> </ol> <ul> <li>This retrospective study included patients with advanced non–small cell lung cancer (NSCLC).</li> <li>There were 422 patients with ALK-rearranged NSCLC and 385 with non–ALK-rearranged NSCLC.</li> <li>The rate of initial VTE was 42.7% in ALK and 28.6% in non-ALK NSCLC.</li> <li>The rate of recurrent VTE was 13.5% in ALK and 3.1% in non-ALK NSCLC.</li> <li>Arterial thrombosis rates were similar in ALK and non-ALK NSCLC (5.0% and 4.4%, respectively).</li> <li>In analyses controlling for time and thrombosis risk factors, the risk of VTE was three times higher and the risk of arterial thrombosis was four times higher among patients with ALK rearrangement.</li> </ul> Al-Samkari H et al. ISTH 2020, Abstract OC 10.2. <a href="https://bit.ly/30KHouB" rel="nofollow" target="_blank">https://bit.ly/30KHouB</a>. Disclosures: Dr. Al-Samkari has no relevant disclosures. Dr. Henry has no relevant disclosures. * * * For more MDedge Podcasts, go to <a href="https://www.mdedge.com/podcasts" rel="nofollow" target="_blank">mdedge.com/podcasts</a> Email the show: <a href="mailto:podcasts@mdedge.com">podcasts@mdedge.com</a> Interact with us on Twitter: <a href="https://twitter.com/mdedgehemonc" rel="noopener nofollow" target="_blank">@MDedgehemonc</a> David Henry on Twitter: <a href="http://bit.ly/2HXI6Lw" rel="noopener nofollow" target="_blank">@davidhenrymd</a>